Share
Global Upstream Bioprocessing Market Size, Share, and Analysis, By Product (Bioreactors/Fermenters, Cell Culture Products, Bioreactors Accessories, Filters, Bags & Containers, and Others), By Workflow (Cell Culture, Cell Separation, and Media Preparation), By Use Type (Multi-use and Single-use), By Mode (In-house and Outsourced), By End-User (Biopharmaceutical Companies, CDMO & CROs, Research & Academic Institutes, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
Global Upstream Bioprocessing Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 14.4% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 12.4 billion and is projected to reach USD 54.4 billion by the completion of 2034.
Upstream bioprocessing refers to the early stages of producing biopharmaceutical products, like therapeutic proteins, vaccines, or antibodies. It includes the process of growing living cells (such as bacteria, yeast, or mammalian cells) in special bioreactors with controlled conditions. These cells have been genetically modified to make the specific biopharmaceutical product. In addition, the upstream process consists of developing cell lines, preparing media, preparing inoculum, and carrying out fermentation or cell culture. Furthermore, variables including pH, temperature, oxygenation, and nutrient availability are observed and adjusted to improve the cell growth and increase the output of production. Thus, the initial stage is important as it lays the groundwork for the subsequent processing steps, in which the desired product is isolated and transformed into its final form for consumption.
Global upstream bioprocessing market is predicted to achieve a value of USD 54.4 billion in the forecasted period, due to the growing need for biopharmaceuticals as a result of the increasing incidence of chronic illnesses and an aging population on a global scale. The need for bioprocessing technologies is pushed by the growth of innovative therapies and personalized medicine methods. Moreover, innovations in bioprocessing technologies like single-use systems and high-throughput screening methods are also impacting the market. The government's initiatives and laws that promote biopharmaceutical innovation also help to boost the worldwide demand for the upstream bioprocessing market. Therefore, the upstream bioprocessing industry is expected to grow further due to the increasing demand for biopharmaceuticals and ongoing innovations in bioprocessing technology.
Source: Fatpos Global
Global upstream bioprocessing market is classified based on Product into Bioreactors/Fermenters, Cell Culture Products, Bioreactors Accessories, Filters, Bags & Containers, and Others. It is projected that the bioreactors/fermenters segment will lead the global upstream bioprocessing market as bioreactors are the primary devices that are used to cultivate living cells or microorganisms to generate biopharmaceutical products such as antibodies, vaccines, and therapeutic proteins. In addition, with the growing interest in biologics, there is a higher demand for more advanced bioreactors to improve control and management of the manufacturing process. In addition, improvements in bioreactor design, such as the incorporation of reusable sensors and data processing capabilities, have increased production output. Furthermore, the demand for mass production of biopharmaceuticals in industrial manufacturing plants requires the use of big bioreactors.
Global upstream bioprocessing market is segmented based on Use Type into Multi-use and Single-use. The single-use segment is expected to dominate the global upstream bioprocessing industry due to several benefits it provides as compared to conventional multi-use systems. In addition, disposable bioprocessing systems like bioreactors, mixers, and containers are created for one-time use, which removes the need for long and expensive cleaning and sterilization procedures. This leads to less time offline and low operational expenses. Besides, disposable systems reduce the chances of cross-contamination, thereby improving the quality and safety of products. Furthermore, the growing use of single-use technologies supports the commitment of the industry to sustainability by lowering water and energy use to lessen environmental impact.
Source: Fatpos Global
Advancements in Biotechnology are Expected to Foster Market Expansion
Growth of biotechnology is transforming the pharmaceutical and biopharmaceutical sectors. The development of new biological products, such as monoclonal antibodies, vaccines, and gene therapies, has played a major role in boosting the growth of the global upstream bioprocessing market. Moreover, an increase in biosimilars, which are biologic items that closely resemble already approved bioprocessing technologies, is also playing a very important role in increasing the adoption of upstream bioprocessing. Furthermore, biotech businesses are investing in new technology to boost the efficiency of production and ensure regulatory compliance.
Increasing Demand for Personalized Medicine and Targeted Therapies Will Aid in the Adoption of Upstream Bioprocessing Market
Increase in the demand for customized medicine and treatments is a major factor that contributes to the growth of the global upstream bioprocessing market. Personalized medical treatments based on individual genetic makeup involve the creation of unique biological medications in custom-made quantities. This requires advanced bioprocessing techniques upstream to guarantee effectiveness and accuracy. In the same manner, special treatments that target specific disease mechanisms can be complicated and involve biologics such as monoclonal antibodies and cell therapies. Thus, to ensure high yield and quality, advanced bioprocessing technologies are required for these complex treatments. Besides, the trend towards tailored medical solutions increases the demand for advanced bioprocessing equipment and analytics, which is responsible for driving the growth of the market.
High Cost and Complexity Associated with Bioprocessing Equipment
One major constraint on the global upstream bioprocessing market is the high cost and complexity of bioprocessing equipment and operations. Developing and sustaining advanced bioprocessing facilities require large capital investment in modern bioreactors, sensors, and automation systems. In addition, operational costs are expensive due to the requirement for highly skilled personnel and ongoing quality control methods. These financial and operational costs might be highly expensive for smaller biopharmaceutical businesses and startups, which limits their capacity to penetrate the market. As a result, these economic and technical boundaries serve as important limitations.
Global upstream bioprocessing market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The global upstream bioprocessing market is led by North America, with a strong focus on the United States, due to its thriving biotechnology industry and advanced technology resources. This region has a strong bioprocessing ecosystem, with top pharmaceutical and biotech firms, along with renowned research centers.
Furthermore, increasing investments in biopharmaceutical manufacturing and research capabilities are driving major growth in the upstream bioprocessing market in the Asia-Pacific region. Nations such as China and India provide affordable manufacturing solutions and are improving their research and development skills. Besides, the growth of the Asia-Pacific region is due to its ability to meet domestic and global demand for biopharmaceuticals through contract manufacturing and research services.
Source: Fatpos Global
Global upstream bioprocessing market underwent major changes due to the COVID-19 pandemic, which accelerated growth and innovation. The urgent need for vaccines and treatments led to record-breaking investments in bioprocessing infrastructure. In addition, companies expanded their production capacities by implementing advanced processes in the early stages to fulfill the global demand for billions of vaccine doses. Moreover, the pandemic highlighted the need for strong supply chains and innovative biomanufacturing methods, which led to high cooperation within the industry and backing from governmental entities. However, the attention given to COVID-19-associated bioprocessing temporarily shifted resources away from other biopharmaceutical projects, which resulted in delays in certain areas.
|
ATTRIBUTE |
DETAILS |
|
Study Period |
2018-2034 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2034 |
|
Historical Period |
2019-2022 |
|
Growth Rate |
CAGR of 14.4% from 2024-2034 |
|
Unit |
Value (USD Billion) |
|
Segmentation |
Main Segments List |
|
By Product |
|
|
By Workflow |
|
|
By Use Type |
|
|
By Mode |
|
|
By End-User |
|
|
By Region |
|
Global upstream bioprocessing market size was valued at USD 12.4 billion in 2023 and is projected to reach the value of USD 54.4 billion in 2034, exhibiting a CAGR of 14.4% during the forecast period.
The global upstream bioprocessing market refers to the equipment, technologies, and services utilized in the production of biopharmaceuticals and biological products, driving advancements in biomanufacturing for therapeutic development and industrial applications.
The Bioreactors/Fermenters segment and the Single-use segment accounted for the largest Global Upstream Bioprocessing Market share.
Key players in the Global Upstream Bioprocessing Market include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, GE Healthcare, Lonza Group Ltd., Eppendorf AG, Corning Incorporated, Applikon Biotechnology BV, PBS Biotech, Inc., Novasep Holding SAS, Fujifilm Diosynth Biotechnologies (a subsidiary of Fujifilm Holdings Corporation), MilliporeSigma (the Life Science business of Merck KGaA), Bio-Rad Laboratories, Inc., Repligen Corporation, and Other Prominent Players.
Advancements in biotechnology and increasing demand for personalized medicine are the factors driving the global upstream bioprocessing market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
